


Aiming to Eradicate Cancer

with Tests that Help Prevent it,
 Detect it Earlier, and Guide Treatment



TOP-LINE DATA FROM BLUE-C FOR NEXT-GENERATION COLOGUARD

	SPECIFICITY INCLUDING NON-ADVANCED FINDINGS	SPECIFICITY INCLUDING NO FINDINGS	CANCER SENSITIVITY	HIGH-GRADE DYSPLASIA SENSITIVITY	ADVANCED PRECANCER SENSITIVITY
DeeP-C cologuard®	87%	90%	92%	69%	42%
BLUE-C next-generation cologuard®	91%	93%	94%	75%	43%

Source: Imperiale TF et al., N Engl J Med (2014), Exact Sciences internal data

UNVEILING NEW BRANDS

Multi-Cancer Early Detection

cancerguard™

Molecular Residual Disease

oncodetect™

OUR VISION & TARGETS: 2027

~15%

compounded annual revenue growth 2022-2027 (excluding COVID and prostate)

20%+

adjusted EBITDA margin in 2027


EXPECTED TO BE FREE CASH FLOW POSITIVE IN Q2 2023



cologuard®

SYNONYMOUS WITH COLON CANCER SCREENING

BASED ON BROAD MOMENTUM IN ADOPTION, UPDATING 2027 TARGET FOR CUMULATIVE PEOPLE SCREENED WITH COLOGUARD FROM 30M+ TO 35M+



UNITING VISIONARY PARTNERS IN THE FIGHT AGAINST CANCER



Agreements provide exclusive license to next-generation technology for ultra-sensitive detection of molecular residual disease and ongoing research



Collaboration creates real-world experience and evidence supporting Exact Sciences' multi-cancer early detection approach

THE MOST POWERFUL COMMERCIAL ENGINE IN DIAGNOSTICS DELIVERING AN EXCELLENT CUSTOMER EXPERIENCE

PATIENTS	HEALTH CARE PROFESSIONALS	HEALTH SYSTEMS	PAYERS	PHARMA
85% brand awareness	370k cumulative providers have ordered	275 electronic connections	780 in-network agreements	60 biopharma partnerships

SAFE HARBOR AND NON-GAAP DISCLOSURES

This presentation contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results; expectations for development of new or improved products and services; our strategies, positioning, resources, capabilities and expectations for future events or performance; and the anticipated benefits of our acquisitions, including estimated synergies and other financial impacts. Risks and uncertainties that could adversely affect the Company's business and prospects, and otherwise cause actual results to differ materially from those anticipated, include without limitation, those described in the filings made by the company with the SEC, including its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. The company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.

In addition to the company's financial results determined in accordance with U.S. GAAP, the company provides non-GAAP measures that it determines to be useful in evaluating its operating performance and liquidity. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company's core operating results and comparison of operating results across reporting periods. Management uses non-GAAP financial measures to establish budgets, manage the Company's business, and in setting incentive and compensation arrangements. The company presents EBITDA, adjusted EBITDA, non-GAAP gross margin, non-GAAP gross profit, and core revenue, and free cash flow. Please refer to the appendix accompanying this presentation for discussion of non-GAAP financial measures and reconciliations to GAAP financial measures.